Citatuzumab Bogatox

DB06072InvestigationalProtein Based Therapies

VB6-845 is a humanized antibody fragment targeting EpCAM fused with the deimmunized form of the cytotoxin Bouganin and is designed for systemic use against metastatic cancer. VB6-845 has demonstrated effective... VB6-845 has demonstrated effective cancer cell killing properties in pre-clinical tests.

Mechanism: VB6-845 is a humanized antibody fragment targeting EpCAM fused with the Company's proprietary deimmunized form of the cytotoxic protein Bouganin, and is designed for systemic use against metastatic cancers.
Curator reviewed
Primary indication: Investigated for use/treatment in cancer/tumors (unspecified).Curator reviewed
Also known as: ANTI-EPCAM ANTIBODY FRAGMENT-BOUGANIN FUSION PROTEIN
Code names: VB6-845

Resolves to

Compound

UNII23J303Z5CACAS945228-49-9

Targets

P16422EPCAM

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Citatuzumab Bogatox, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account